Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Legal Services Should Be a Component of Standard Cancer Care

March 1, 2007
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 3
Volume 16
Issue 3

It is commonly accepted that nonmedical issues, such as loss of benefits, employment concerns, and debt management, may negatively impact the outcomes of patients fighting cancer.

NEW YORK—It is commonly accepted that nonmedical issues, such as loss of benefits, employment concerns, and debt management, may negatively impact the outcomes of patients fighting cancer. According to a recent survey co-funded by the Lance Armstrong Foundation and the Centers for Disease Control and Prevention (CDC), access to legal assistance should be part of the continuum of cancer care.

The survey was conducted by LegalHealth, a division of the New York Legal Assistance Group, which provides free legal assistance to low-income seriously ill individuals (www.legalhealth.org). "The CDC has indicated that legal service is one of the first things HIV-infected people need. And our survey shows that the same is true for cancer patients," Randye Retkin, director of LegalHealth, told ONI.

LegalHealth worked with law students, a professional nonprofit evaluator, and a public health researcher to create and administer the survey, which queried 51 cancer patients (age 29 to 82) who had been assisted by LegalHealth. The survey asked whether legal services helped reduce their worries, how it affected their financial situation and their loved ones, and if it helped them maintain their treatment regimens.

Ms. Retkin said that the financial implications of cancer left many of these patients in extremely vulnerable situations, struggling to continue working despite their illness or having to deal with the loss of a job. "Perhaps the most compelling statistic was that 78% of the individuals surveyed said that their diagnosis of cancer actually created their legal difficulties," she said. The study also found that 83% said legal services helped reduce stress, 51% said the services had a positive effect on their financial situation, and 33% reported that legal services helped their families or loved ones. "Many of our clients were just keeping their heads above water, but after a cancer diagnosis, their legal and financial situations spiraled out of control," Ms. Retkin said. Patients also said that legal services helped them keep medical appointments (22%) and maintain their treatment regimens (23%).

LegalHealth attorneys hold weekly or monthly legal clinics in New York City hospitals and community-based facilities, six of which focus on cancer. In 2006, they assisted approximately 2,300 patients, 600 of whom were diagnosed with cancer. "Our educational program trains physicians to understand the legal issues affecting their patients, and we also provide consumer training to help patients cope with potential legal issues," she said.

Along with hospitals and community facilities, LegalHealth also partners with educational and advocacy groups such as CancerCare, Inc. "We provide a monthly on-site clinic at CancerCare, working directly with cancer patients. We have a great relationship with CancerCare. They've become a big source of referrals for us," Ms. Retkin said.

Articles in this issue

Peptide-Based Breast Ca Vaccines Promising in Early Trials
Diagnostic Dilemma: GI Disease
Imatinib Responses in CML May Take Time
IV Vidaza Approved; Oral Formulation to Be Tested
Study Confirms Avastin Advantage in Advanced NSCLC
Legal Services Should Be a Component of Standard Cancer Care
Mouse Virus Evidence Suggests Viral Basis for Breast Ca
Groups Oppose Ruling on Access to Experimental Drugs
Satellite Allows Digital Mammography Screening for Rural Native Americans
Nexavar Effective in Advanced HCC: Phase III Trial Stopped
H&N Ca Patients With CR to CRT May Not Need Surgery
Two Sets of Researchers Find Herceptin Cost Effective
Family-Based Testing Strategy May Better Detect HNPCC
More 'Promacs,' Worse Outcome
Brachytherapy Balloon Can Be Placed After Final Pathology

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
Related Content

Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.

Sunvozertinib Earns FDA Accelerated Approval in EGFR Exon 20+ NSCLC

Russ Conroy
July 2nd 2025
Article

Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.


Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.


The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.

Comparing CAR T Safety, Efficacy in Relapsed/Refractory Multiple Myeloma

Roman Fabbricatore
July 2nd 2025
Article

The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.


Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.


Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 (NCT03761108) trial.

Linvoseltamab Earns FDA Accelerated Approval for R/R Multiple Myeloma

Roman Fabbricatore
July 2nd 2025
Article

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 trial.


The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

SonoClear System Earns Breakthrough Designation for Intracranial Procedures

Roman Fabbricatore
July 2nd 2025
Article

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

Related Content

Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.

Sunvozertinib Earns FDA Accelerated Approval in EGFR Exon 20+ NSCLC

Russ Conroy
July 2nd 2025
Article

Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.


Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.


The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.

Comparing CAR T Safety, Efficacy in Relapsed/Refractory Multiple Myeloma

Roman Fabbricatore
July 2nd 2025
Article

The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.


Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.


Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 (NCT03761108) trial.

Linvoseltamab Earns FDA Accelerated Approval for R/R Multiple Myeloma

Roman Fabbricatore
July 2nd 2025
Article

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 trial.


The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

SonoClear System Earns Breakthrough Designation for Intracranial Procedures

Roman Fabbricatore
July 2nd 2025
Article

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.